Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
On November 17, 2025, Mirum Pharmaceuticals, Inc. (the "Company") received a Paragraph IV Certification Notice Letter (...
New data reinforce Mirum's commitment to advancing therapies and improving the lives of patients across diverse rare liver ...
Cantor Fitzgerald analyst Josh Schimmer maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price...
Citizens analyst Jonathan Wolleben maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Outperform and raises the pri...
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises t...
Mirum Pharmaceuticals (NASDAQ:MIRM) raises FY2025 sales outlook from $490.000 million-$510.000 million to $500.000 million-$510...
Mirum Pharmaceuticals (NASDAQ:MIRM) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of...
